Advertisement

Expert Point of View: Alex A. Adjei, MD, PhD


Advertisement
Get Permission

Alex A. Adjei, MD, PhD

Alex A. Adjei, MD, PhD

Alex A. Adjei, MD, PhD, of the Mayo Clinic, Rochester, Minnesota, also commented on this phase I study of AMG 510. “Although it is a little bit early to tell and the number of patients with non–small cell lung cancer treated is still small, AMG 510 is the first potential true breakthrough in the quest for effective therapies for KRAS-mutant tumors. Although this agent targets only a subset of KRAS-mutant tumors [G12C], representing approximately 15% to 20% of KRAS mutations in lung cancer, it will undoubtedly serve as a paradigm for targeting this previously ‘undruggable’ oncogene.” 

DISCLOSURE: Dr. Adjei reported no conflicts of interest.


Related Articles

Novel KRAS Inhibitor Shows Activity in Early Study of Advanced Non–Small Cell Lung Cancer

The investigational KRAS inhibitor AMG 510 yielded clinical activity in patients with advanced non–small cell lung cancer (NSCLC), according to updated results of a small ongoing phase I trial reported at the 2019 International Association for the Study of Lung Cancer (IASLC) World Conference on...

Advertisement

Advertisement



Advertisement